- Vivity complements Alcon’s existing IOL portfolio by
providing an additional option for cataract patients to treat
presbyopia
- A first-of-its-kind, non-diffractive lens that offers a
continuous extended range of vision while maintaining a low
incidence of visual disturbances, like a monofocal IOL
- Vivity launches in select European countries with additional
markets coming throughout 2020
Regulatory News:
Alcon (SIX/NYSE:ALC), the global leader in eye care announced
AcrySof® IQ Vivity®, a first-of-its-kind intraocular lens (IOL) is
now commercially available in select European markets, with
additional countries to follow throughout 2020.
The latest innovation in Alcon’s portfolio of
presbyopia-correcting IOLs (PC-IOLs), Vivity is the
first-of-its-kind, extended range of vision IOL that uses
non-diffractive design called X-WAVE™ technology to reduce a
cataract patient’s dependency on glasses. According to
patient-reported outcomes, Vivity enables high-quality vision at
far and intermediate ranges as well as functional up-close vision.
Available in spherical and toric designs, Vivity is built on
Alcon’s proven AcrySof IQ IOL platform that has been implanted in
more than 120 million eyes globally.
“We are excited to introduce Vivity because it addresses some
common concerns of surgeons and cataract patients alike when
considering presbyopia-correcting IOLs (PC-IOLs),” said Michael
Onuscheck, President, Global Business and Innovation at Alcon.
“This novel non-diffractive lens option provides PC-IOL performance
with the ease of monofocal patient management.”
Alcon’s proprietary non-diffractive technology uses two smooth
surface transition elements on the anterior surface of the IOL that
work simultaneously to create continuous, extended range of vision
rather than separate focal points. Recent clinical trials found
Vivity provides very good quality of vision at distance and
intermediate ranges in bright and dim light. Without glasses, 94
percent of patients reported good or very good vision at distance,
and 92 percent reported good or very good vision at arm’s length.1
Additionally, patients using Vivity reported such low levels of
starbursts, halos and glares that Vivity’s visual disturbance
profile is comparable to a monofocal lens.2
Following FDA approval in February, Alcon will begin launching
Vivity with select U.S. ophthalmologists over the coming months,
with broader U.S. availability to be announced later this year.
“As we continue to focus on the ongoing launch of PanOptix® in
the U.S., we look forward to launching Vivity as a complementary
lens in more markets throughout the year,” added Onuscheck.
Alcon is the leading manufacturer of intraocular lenses. Of the
20 million cataract procedures conducted globally each year, only
4% of patients receive PC-IOLs. Now, with a lens that offers a
visual disturbance profile comparable to the industry-leading
AcrySof IQ monofocal lens, Vivity offers cataract surgeons another
option to deliver better outcomes for their patients.
About Cataracts
A cataract is a cloudy area in the natural lens of the eye that
affects vision. As a cataract develops, the eye’s lens gradually
becomes hard and cloudy allowing less light to pass through, which
makes it more difficult to see. The vast majority of cataracts
result from normal aging, but radiation exposure, taking steroids,
diabetes and eye trauma can accelerate their development.3
Cataracts are the most common age-related eye condition and the
leading cause of preventable blindness.4 Cataracts are treated by
removing the eye’s cloudy natural lens and surgically replacing it
with an intraocular lens or IOL. More than 98% of cataract
surgeries are considered successful, and patients typically can
return to their normal routines within 24 hours.5
About Presbyopia
Presbyopia is a common, age-related vision condition in which
people have difficulty focusing on things up close. It involves the
gradual loss of the eye’s ability to focus on close objects, such
as smart phones, computers, books and menus.6 Almost everyone will
experience presbyopia to some degree as they age, with symptoms
often first appearing as an individual enters their 40s and
continues to worsen into their 60s.6 The condition is not a
disease, so it cannot be cured; however, there are safe and
effective ways to correct presbyopia, including eye glasses,
contact lenses or refractive surgery.
About Vivity
The non-diffractive AcrySof™ IQ Vivity™ Extended Vision
Posterior Chamber Intraocular Lens Model DFT015 (referred to as
AcrySof™ IQ Vivity™ IOL) is an UV-absorbing and blue light
filtering foldable intraocular lens (IOL). This IOL, compared to a
monofocal IOL, provides an extended range of vision from distance
to near without increasing the incidence of visual
disturbances.
Potential side effects: As with any surgery, there is an
implicit risk, whether or not the IOL is implanted. The
complications of the IOL implantation surgery ranges from minor
side effects (usually temporary) to serious complications. Patients
with previous illnesses or disorders (such as chronic infections of
the eye or eyelids, or diabetes) may present a higher risk of
complications. Temporary surgical complications include, but are
not limited to, reactions to medications such as irritation or mild
allergic response, bleeding, redness, itching of the eye,
sensitivity to light, swelling, Corneal edema (swelling of the
cornea), problems with the iris, cell growth in the IOL, and an
increase temporary eye pressure. There is a small risk of needing
further surgical treatment (such as IOL replacement implanted by a
different one or surgery to improve vision) after the implantation
of the initial IOL.
A toric IOL corrects astigmatism when it is placed in the
correct position within the eye and remains in the intended
position. If the IOL is not correctly positioned and does not
remain in its intended position to correct astigmatism, you may
experience visual distortions, where curved lines appear inclined
or flat surfaces will appear curved. These visual distortions can
make you dizzy.
Disclaimer
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
References
- Alcon Data on file, 2019.
- Alcon Data on file, 2019.
- National Institutes of Health (NIH), National Eye Institute
(NEI), Causes of Cataract. Accessed March 5, 2020. Available at:
https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/cataracts/causes-cataract.
- Centers for Disease Control and Prevention, Vision Health
Initiative. Accessed March 5, 2020. Available at:
https://www.cdc.gov/visionhealth/basics/ced/index.htm.
- Cleveland Clinic, Cataracts. Accessed March 5, 2020. Available
at:
https://my.clevelandclinic.org/health/diseases/8589-cataracts.
- Mayo Clinic, Presbyopia. Accessed August 12, 2019. Available
at:
https://www.mayoclinic.org/diseases-conditions/presbyopia/symptoms-causes/syc-20363328.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
Connect with us on
Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200311005846/en/
Investor Relations Christina
Cheng + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024